Better Coronavirus Stock: Moderna vs. Sorrento Therapeutics
Many drugmakers are rushing to develop potential therapies and vaccines for novel coronavirus disease COVID-19. But two of them have been in the spotlight in recent days. Moderna (NASDAQ: MRNA) announced positive interim data on Monday from an early-stage clinical study of its COVID-19 vaccine candidate. Last week, Sorrento Therapeutics (NASDAQ: SRNE) reported results from a preclinical study of an antibody that holds the potential to completely neutralize the novel coronavirus.
As you might expect, both Moderna and Sorrento have seen their stocks skyrocket. Moderna's shares have nearly quadrupled year to date, while shares of Sorrento have soared more than 70%. But which of these two coronavirus-focused biotech stocks is the better pick for investors now?
Image source: Getty Images.
Source Fool.com
